Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 2 · 28.6%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest reported · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest… compared with placebo (moderate certainty).

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
RR 0.97 [0.58, 1.62]
2 studies · 3439 participants
Moderate

Active tuberculosis: started on tuberculosis treatment · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in active tuberculosis: started on tuberculosis treatment compared with placebo (moderate certainty).

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
RR 1.1 [0.92, 1.33]
3 studies · 3687 participants
Moderate

Latent tuberculosis · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in latent tuberculosis compared with placebo (moderate certainty).

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
RR 1.01 [0.85, 1.21]
4 studies · 3831 participants
Moderate

Serious adverse effects · HIV‐positive and ‐negative adults and children

MVA85A showed no clear difference in serious adverse effects compared with placebo (high certainty).

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
RD 0
3 studies · 3692 participants
High

Adverse effects Skin/local reactions · HIV‐positive and ‐negative adults and children

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3187 participants
Moderate

Adverse effects of any severity (systemic symptoms) · HIV‐positive and ‐negative adults and children

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 144 participants
Low

Adverse events of any severity · HIV‐positive and ‐negative adults and children

MVA85A leads to higher adverse events of any severity compared with placebo (high certainty).

1 finding from 1 review

MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
RR 1.05 [1.02, 1.08]
4 studies · 3836 participants
High